OLD National Bancorp IN Has $783,000 Stock Position in AstraZeneca PLC $AZN

OLD National Bancorp IN lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 14.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 11,206 shares of the company’s stock after selling 1,892 shares during the quarter. OLD National Bancorp IN’s holdings in AstraZeneca were worth $783,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AZN. Larson Financial Group LLC lifted its holdings in AstraZeneca by 297.9% in the first quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after buying an additional 289 shares during the period. FNY Investment Advisers LLC bought a new position in shares of AstraZeneca in the 1st quarter worth about $29,000. Costello Asset Management INC acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $29,000. Highline Wealth Partners LLC boosted its position in shares of AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock valued at $31,000 after purchasing an additional 340 shares in the last quarter. Finally, Maseco LLP acquired a new stake in AstraZeneca during the second quarter worth approximately $34,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Saturday, September 27th. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Trading Up 0.2%

NASDAQ AZN opened at $85.49 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $86.57. The business has a 50 day moving average price of $78.32 and a 200-day moving average price of $73.12. The company has a market cap of $265.14 billion, a price-to-earnings ratio of 32.14, a P/E/G ratio of 1.57 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca’s revenue was up 16.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.24 EPS. As a group, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s payout ratio is presently 37.97%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.